logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Clostridium Difficile Diarrhea

    Medications for Clostridium Difficile Diarrhea

    FiltersReset Filters
    4 results

    • firvanq

      (vancomycin hydrochloride)
      Azurity Pharmaceuticals, Inc
      Usage: FIRVANQ is indicated for treating Clostridium difficile-associated diarrhea and Staphylococcus aureus enterocolitis (including MRSA) in adults and pediatric patients under 18. It must be administered orally for these infections, and is not effective for other types of infections. Use should be judicious to prevent drug resistance.

    • vancocin

      (vancomycin hydrochloride)
      ANI Pharmaceuticals, Inc.
      Usage: VANCOCIN is indicated for treating Clostridioides difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus (including MRSA) in patients under 18. It must be administered orally for these infections, as parenteral use is ineffective. It's reserved for proven or suspected bacterial infections to prevent resistance.

    • vancomycin hydrochloride

      (vancomycin hydrochloride)
      Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
      Usage: Vancomycin hydrochloride capsules are indicated for treating Clostridioides difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) in patients under 18 years. They are effective only when administered orally and are not suitable for other infection types.

    • vancomycin hydrochloride for oral solution

      (vancomycin hydrochloride)
      Wilshire Pharmaceuticals, Inc.
      Usage: Vancomycin hydrochloride is indicated for treating Clostridium difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus (including MRSA) in adults and pediatric patients under 18. It must be administered orally for these conditions and is ineffective for other infections when given parenterally.